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Introduction: New-onset left bundle branch block (LBBB) and conduction defects leading to permanent pacemaker (PPM) implantation are 
important complications after transcatheter aortic valve replacement (TAVR). There is paucity of data on the impact of these complications on left 
ventricular systolic function after TAVR.
methods: We reviewed data from a total of 137 patients undergoing TAVR using the Edward SAPIEN Valve. Patients with pre-existing LBBB and prior 
PPM were excluded from the study (n= 36). Remaining 101 patients were divided into two subgroups; A: patients without any persistent conduction 
defect or PPM implantation after TAVR (n=64) and subset B: patients with new-onset LBBB and PPM implantation after TAVR (n= 37). Ejection 
fraction (EF) was compared at baseline, 1 month, 6 month and 1 year post-TAVR intervals.
results: The mean EF at baseline of patients in our study was (SD: 57.19 % (SD: 15.66). Patients in subgroup B had a prolonged QRS (120.43 + 28.93 
ms) as compared to patients in subgroup A (104.42 + 21.99 ms, p = 0.005) at baseline. No differences in echocardiographic parameters were detected 
at baseline. There was a significant improvement in EF in patients of subgroup A at 1-month after TAVR (57.59 + 15.97 % at baseline to 60.67 + 13.29 
%, p = 0.043), whereas there was no significant improvement in patients of subset B (57.19 + 16.56 % at baseline to 59.19 + 13.91 %, p = 0.39). 
Similarly at 6 month post-TAVR patients in subgroup A experienced a significant improvement in EF (from 58.55 + 14.82 % at baseline to 62.95 + 10.54 
%, n = 44, p = 0.01) and patients in subgroup B did not have improvement in EF (58.28 + 15.21 at baseline to 59.52 + 16.39, n = 25, p = 0.49). The 
improvement in EF persisted at 1 year post-TAVR in subgroup A (58.50 + 15.41 % at baseline to 63.25 + 10.38 %, n= 44, p = 0.024), whereas in subset 
B there was persistent lack of improvement in EF (57.26 + 15.61 % at baseline to 55.61 + 14.39 %, n= 23, p = 0.28).
conclusion: EF improves after TAVR in patients without new conduction defects. In patients with persistent LBBB and conduction defects leading to 
PPM implantation there is no improvement in EF on follow up after TAVR.
